Want to see CAH full AI Analyst Report?
Profit by Segment
Shows profitability across different business units, highlighting which areas drive earnings and where there might be challenges or opportunities for growth.Pharmaceutical profit shows durable multi-year improvement and clear operational gearing — management’s raised, narrowed Pharma profit guidance and cited quarter-to-quarter momentum imply much of the upside is sustainable. That said, the series contains dramatic late‑2025 spikes in both Pharma and Medical that read like one‑time accounting or deal-related items; Medical remains volatile and low‑margin otherwise. For valuation, focus on the steady Pharma run‑rate and cash‑flow improvement, but watch tariff/refund uncertainty, SG&A/interest pressure and revenue‑mix risks that could swing short‑term profits.
Date | Pharmaceutical | Medical |
|---|---|---|
Jun 30, 2026 | $645.00M | $150.00M |
Mar 31, 2026 | $784.00M | $25.00M |
Dec 31, 2025 | $2.26B | $135.00M |
Sep 30, 2025 | $667.00M | $530.00M |
Jun 30, 2025 | $535.00M | $70.00M |
Mar 31, 2025 | $662.00M | $39.00M |
Dec 31, 2024 | $531.00M | $18.00M |
Sep 30, 2024 | $530.00M | $8.00M |
Jun 30, 2024 | $482.00M | $47.00M |
Mar 31, 2024 | $580.00M | $20.00M |